Table 3.
Clinical and pathological characteristics of nCT-treated patients and matched controls.
| Variable | After Matching | |
|---|---|---|
| nCT (60) | Non-nCT (60) | |
| Histology | ||
| Adenocarcinoma, n (%) | 37 (61.6) | 41 (68.3) |
| Squamous cell carcinoma, n (%) | 20 (33.3) | 9 (15) |
| Neuroendocrine carcinoma, n (%) | - | 7 (11.6) |
| Other, n (%) | 3 (5) | 3 (5) |
| cTNM | ||
| T1N0M0 | - | 40 |
| T1N0M1 | 3 | - |
| T1N1M0 | 1 | - |
| T1N2M0 | 5 | 1 |
| T1N3M0 | 2 | - |
| T2N0M0 | - | 11 |
| T2N0M1 | 1 | - |
| T2N1M0 | 4 | 2 |
| T2N2M0 | 12 | 3 |
| T3N0M0 | 1 | 1 |
| T3N1M0 | 3 | - |
| T3N2M0 | 15 | - |
| T4N0M0 | - | 2 |
| T4N0M1 | 5 | - |
| T4N1M0 | 2 | - |
| T4N2M0 | 6 | - |
| (y)pTNM | ||
| T0N0M0 | 7 | - |
| T1N0M0 | 17 | 32 |
| T1N1M0 | 2 | - |
| T1N2M0 | 5 | - |
| T2N0M0 | 15 | 16 |
| T2N1M0 | 5 | 1 |
| T2N2M0 | 1 | 5 |
| T3N0M0 | 4 | 4 |
| T3N1M0 | 1 | - |
| T3N2M0 | 1 | - |
| T4N0M0 | 2 | 1 |
| T4N1M0 | - | 1 |
| Clinical stage | ||
| I | - | 50 |
| IIA | - | 1 |
| IIB | 6 | 3 |
| IIIA | 30 | 6 |
| IIIB | 15 | - |
| IV | 9 | - |
| Pathological stage | ||
| 0 | 7 | - |
| I | 25 | 47 |
| IIA | 7 | 1 |
| IIB | 11 | 5 |
| IIIA | 9 | 7 |
| IIIB | 1 | - |